Business at the laboratory service provider and pharmaceutical supplier Sartorius is still in full swing.
Sartorius is currently experiencing a real boom in orders from manufacturers of vaccines and corona tests, to which Sartorius supplies important accessories.
Incoming orders for the newcomer to the Dax rose in the first nine months by around 68 percent year-on-year to just under 3.3 billion euros, as Sartorius announced on Wednesday in Göttingen.
Göttingen - Lower Saxony's turnover was a good 2.5 billion euros, which was a good 50 percent more than a year earlier when adjusted for currency effects.
Analysts had expected slightly less proceeds and lower earnings.
Adjusted earnings before interest, taxes, depreciation and amortization (Ebitda) climbed to 866 million euros, an increase of over 77 percent compared to the previous year.
The corresponding margin increased to 34.3 (previous year: 29.1) percent.
The bottom line was that the shareholders accounted for a profit adjusted for special effects of almost 407 million euros, almost twice as much as in the same period of the previous year.
Sartorius confirmed the targets for the full year 2021.
dpa